<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811822</url>
  </required_header>
  <id_info>
    <org_study_id>GMI-1271-230</org_study_id>
    <nct_id>NCT02811822</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma</brief_title>
  <official_title>A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlycoMimetics Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlycoMimetics Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate GMI-1271, a specific E-selectin antagonist, in multiple myeloma as
      adjunct to standard of care chemotherapy used to treat this disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by frequency, severity and relatedness of AEs</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Assessed by frequency, severity and relatedness of AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Overall Response Rate = Stringent Complete Response + Complete Response + Very Good Partial Response + Partial Response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate = Stringent Complete Response + Complete Response + Very Good Partial Response + Partial Response + Minimal Response + Stable Disease</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time versus plasma concentration profile of GMI-1271</measure>
    <time_frame>up to Day 23 of Cycle 1 (each cycle is 21 or 28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GMI-1271</intervention_name>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_label>Dose 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females â‰¥ 18 years of age

          2. Confirmed diagnosis of Multiple Myeloma

          3. Subjects with progressive MM who have received at least 1 prior therapy and who have
             already undergone or are not expected to undergo hematopoietic stem cell
             transplantation

          4. Subjects previously treated with an IMiD-based regimen or ineligible for an IMiD-based
             treatment regimen

          5. Subjects must be receiving treatment with a proteasome inhibitor-based regimen
             (bortezomib-based or carfilzomib-based)

          6. Adequate hepatic, renal, and cardiac function

        Exclusion Criteria:

          1. Intolerant to bortezomib or carfilzomib

          2. Progressing evidence of end organ damage attributed to the underlying disease

          3. Plasma cell leukemia

          4. Congestive heart failure

          5. Acute active infection

          6. Non-hematologic malignancy within the past 3 years except: a) adequately treated basal
             cell or squamous cell skin cancer, b) carcinoma in situ of the cervix, or c) prostate
             cancer with stable PSA

          7. Significant peripheral neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael O'Dwyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Ireland - Galway</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GlycoMimetics, Inc.</last_name>
    <email>clinicaltrials@glycomimetics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lea Hahn</last_name>
      <phone>+45 7940 6757</phone>
    </contact>
    <investigator>
      <last_name>Torben Plesner, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik/Abt. Innere Medizin V</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klara Sarr</last_name>
      <phone>+496221/566588</phone>
    </contact>
    <investigator>
      <last_name>Marc-Steffen Raab, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital, Wilton</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra O'Hare</last_name>
      <phone>+021 4920051</phone>
    </contact>
    <investigator>
      <last_name>Mary E Cahill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Kenny</last_name>
      <phone>+01 809 2080</phone>
    </contact>
    <investigator>
      <last_name>John Quinn, MB PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Ireland - Galway</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Walsh</last_name>
      <phone>+0915 44544</phone>
    </contact>
    <investigator>
      <last_name>Michael O'Dwyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Marshall</last_name>
      <phone>0114 2713339</phone>
    </contact>
    <investigator>
      <last_name>Andrew Chantry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint James's University Hospital Leeds</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Taylor</last_name>
      <phone>011 3206 7420</phone>
    </contact>
    <investigator>
      <last_name>Christopher Parrish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Jennings</last_name>
      <phone>020 344 72930/12929</phone>
    </contact>
    <investigator>
      <last_name>Rakesh Popat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GMI-1271</keyword>
  <keyword>bortezomib</keyword>
  <keyword>carfilzomib</keyword>
  <keyword>multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

